Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Medical University, Silesian Centre for Heart Diseases,Zabrze, Poland.
Kardiol Pol. 2010 Oct;68(10):1124-31.
severe symptomatic aortic valve stenosis is an unequivocal indication for surgical valve replacement, assuring symptoms relief and increasing survival. About one third of elderly patients is not being operated due to, among others, high peri-procedural risk and comorbidities. Transcatheter aortic valve implantation (TAVI) has recently become a valuable therapeutic option for these patients.
to present early results of first TAVI Edwards-Sapien procedures in our hospital, performed in symptomatic patients with high operational risk or other contraindications for conventional surgery, as well as the results of 6-month follow-up.
twelve patients referred for TAVI were included in the analysis. The valve was implanted in 11 patients and in 1 patient the procedure was finished with aortic valve valvuloplasty. Eight (72.7%) patients underwent transapical (TA) and 3 (27.3%) patients transfemoral (TF) TAVI. Seven (63.6%) 26 mm valves and 4 (34.4%) 23 mm valves were implanted.
the efficacy of the procedure was 92%: 100% in the TA group, and 75% in the TF group. During the procedure 1 patient developed ventricular fibrillation. Atrial fibrillation and right ventricle perforation by the endocavitary electrode was observed in another patient. Prolonged wound healing occurred in 4 patients and contrast-induced renal failure occurred in 2 patients. There were no deaths at 30-days. Two patients had a pacemaker implanted during hospitalisation. A significant improvement of echocardiographic parameters was observed: maximum gradient across the aortic valve was 104.4 ± 23.9 mm Hg before vs 25.2 ± 6.1 mm Hg after the intervention, p = 0.000001, mean gradient - 63.8 ± 18.3 vs 12.7 ± 3.7 mm Hg, p = 0.000004, and valvular surface - 0.7 ± 0.2 vs 1.5 ± 0.2 cm2, p = 0.000106, respectively. During the 6-month follow-up period 1 patient died of multiorgan failure and 6 patients required another hospitalisation. After 6 months an improvement in physical capacity was observed in all but one patients (NYHA II - 9 patients, NYHA III - 1 patient).
严重的症状性主动脉瓣狭窄是手术瓣膜置换的明确指征,可以缓解症状并提高生存率。由于围手术期风险高和合并症等原因,约三分之一的老年患者未接受手术。经导管主动脉瓣植入术(TAVI)最近已成为这些患者的一种有价值的治疗选择。
介绍我们医院首例 Edwards-Sapien 经导管主动脉瓣植入术(TAVI)的早期结果,这些患者为有症状且手术风险高或有其他传统手术禁忌证的高危患者,以及 6 个月随访结果。
纳入了 12 例因 TAVI 而转诊的患者。在 11 例患者中植入了瓣膜,在 1 例患者中瓣膜成形术完成了手术。8 例(72.7%)经心尖(TA)入路,3 例(27.3%)经股动脉(TF)入路。植入了 7 个 26mm 瓣膜和 4 个 23mm 瓣膜。
手术成功率为 92%:TA 组为 100%,TF 组为 75%。手术过程中 1 例患者发生心室颤动。另 1 例患者出现心房颤动和心腔内电极致右心室穿孔。4 例患者出现伤口愈合延长,2 例患者出现对比剂诱导的肾功能衰竭。30 天内无死亡。2 例患者在住院期间植入了起搏器。超声心动图参数显著改善:主动脉瓣跨瓣最大梯度由术前的 104.4±23.9mmHg 降至术后的 25.2±6.1mmHg,p=0.000001,平均梯度由术前的 63.8±18.3mmHg 降至术后的 12.7±3.7mmHg,p=0.000004,瓣口面积由术前的 0.7±0.2cm2 增加至术后的 1.5±0.2cm2,p=0.000106。在 6 个月的随访期间,1 例患者死于多器官衰竭,6 例患者再次住院。6 个月后,除 1 例患者外(NYHA II 级 9 例,NYHA III 级 1 例),所有患者的体力均有改善。